Last reviewed · How we verify
Benazepril/Valsartan
Benazepril/Valsartan is a combination of an ACE inhibitor and an angiotensin II receptor blocker that reduces blood pressure by inhibiting two complementary pathways of the renin-angiotensin-aldosterone system.
Benazepril/Valsartan is a combination of an ACE inhibitor and an angiotensin II receptor blocker that reduces blood pressure by inhibiting two complementary pathways of the renin-angiotensin-aldosterone system. Used for Hypertension.
At a glance
| Generic name | Benazepril/Valsartan |
|---|---|
| Sponsor | Mario Negri Institute for Pharmacological Research |
| Drug class | ACE inhibitor/Angiotensin II receptor blocker combination |
| Target | ACE (angiotensin-converting enzyme) and AT1 receptor (angiotensin II type 1 receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Benazepril inhibits angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to angiotensin II, while valsartan blocks the angiotensin II type 1 (AT1) receptor directly. Together, these agents provide dual blockade of the renin-angiotensin-aldosterone system, resulting in greater vasodilation, reduced aldosterone secretion, and more effective blood pressure reduction than either agent alone.
Approved indications
- Hypertension
Common side effects
- Dizziness
- Headache
- Fatigue
- Hyperkalemia
- Cough
- Hypotension
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study
- Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome (PHASE2)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Coronavirus (COVID-19) ACEi/ARB Investigation (PHASE4)
- Preventing Microalbuminuria in Type 2 Diabetes (PHASE3)
- Is There an Adverse Drug Reaction Between Renin-Angiotensin System Blockade and Inhaled Anesthetics (PHASE4)
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Benazepril/Valsartan CI brief — competitive landscape report
- Benazepril/Valsartan updates RSS · CI watch RSS
- Mario Negri Institute for Pharmacological Research portfolio CI